Jump to content

Bevo

Legacy Members
  • Posts

    15033
  • Joined

  • Last visited

Everything posted by Bevo

  1. Saw this on Nextdoor and it reminded me of this thread Jeff Laura Voorhis (Zarrella) Volente · This is for the Volente/ Booth Circle area. I have lost 2 beloved dogs due to predators in the last week. Winston was last week and Brutus was killed on Friday night. Both dog were male healthy and strong. Each weighed more than 20 pounds. Brutus was carried off leaving a blood trail. I could not find his body. I found a patch of pulled off hair that looks like Winston back up in a cove. I am posting this because these events seems out of place. My family has owned property in Volente for over 60 years and we have never experienced anything like it. I spoke with some wildlife experts, could be coyotes, but they were saying sounds like a mountain lion. I will be calling Parks and wildlife on Monday. If this predator has developed a taste for pets, it could escalate to anyone. Please do not panic, but be more vigilante and aware of your surrounding and your pets. Add a comment...
  2. One thing that is kind of interesting is that drug company research cost is pretty low. They would rather focus on development than pure research if given the opportunity. Research is a huge expense so they let research find targets, let biotech establish the target as a legitimate drug opportunity, and then partner with biotech to get it to market. However, biotech usually only has a biologic solution like a monoclonal antibody. That's great because it gets to the market quickly, but it isn't a great solution because the COGS are extremely high for monoclonal antibodies, and patients would rather take a pill than get an infusion. So, while the monoclonal is on the market, pharma will use its huge bank of chemical libraries and see if it can find a hit. Then, it will optimize any hit through combinatorial libraries which are similar in structure to the hit. So, pharma doesn't waste much money on basic research but it pours a shit-ton of money into development (which includes clinical trials). Still, pharma spends a ton of money on marketing. As a consultant (20yrs ago), I saw that the best correlation to sales was the number of papers on a drug. Sales force size, advertising budgets, medical science liaisons, etc. weren't well correlated. So, I worked to get pharma on board with getting papers out there. It is interesting though, how much pharma still focuses on sales. I have a buddy who is heavily involved with Dupixent (a monoclonal antibody with high COGS) and sales on such a drug is more about helping get patient insurance to pay for the product. Cost without insurance and discount cards is about $5000/mo or $60,000/yr. so it makes since to get a sales rep to help individual patients get the drug. So, the sales rep is helping the doctor write the letters to insurance and he is helping patients get a drug which they need and spending less time convincing the doctor to prescribe it.
  3. That is a really, really dumb intro to an article. Of course the P/E ratios of pharmaceutical companies is higher than commodity companies. Look at the numbers though and tell me what's out of line? https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html
  4. The code is more rules than what you just call guidelines.
  5. It should rotate between Atlanta, New Orleans, and Dallas.
  6. My best friend in graduate school went there and my dad did his residency there, so I have nothing but goodwill. Anyway, I think the point is that if Indiana had a mascot, they would have won it all.
  7. Indiana is thinking about re-introducing a mascot. The front runner is to bring back the american bison which they last had as a mascot in the 1960s.
  8. The 6-6, 300-pound M’Ba posted 30 tackles this season. Former highly-ranked JUCO recruit who transferred to Purdue from Auburn.… I didn’t click through. Was Auburn the Juco?
  9. Yeah, unfortunately doctors don’t know the pricing of all the things they prescribe. I prescribed Minocycline in tablets (I think) and later found out that the capsules were $100 cheaper.
  10. That isn’t true and if you spoke like that in public people would call you a prick. I was explaining the marketplace and you just want to whine and argue.
  11. Yeah, next time it will be different. And if he handles himself with the same maturity he has shown after he got into the dog house at Texas, I'm sure things will work out better for him with a change of scenery.
  12. Option number 3 - I'm just being a smartass since I wasn't sold on them when they were recruited.
  13. Insulin basically comes from three manufacturers who keep prices high. They have switched the market from less expensive human and animal insulins to more expensive insulin analogs. To combat the issue we need to get clinicians to prescribe lower-cost insulins. We also need to get biosimilar insulins through the FDA and figure out a way to get them distributed more efficiently. For every $100 spent on insulin, $40 goes to parties in the distribution chain. And finally, we need to figure out a way to address the patent system - the patent strategy to increase the patent life of a drug by filing additional patents I think is acceptable. But those additional patents probably should have shorter lifespans than the original patent. I don’t know how to do that but I’m sure @TwiceHorn has some ideas. I’m stuck using a phone so I can’t give you actual links on where pharma makes their money. One fact I can recall though is that generic drugs account for ~90% of prescription drugs dispensed, but they account for only ~30% of total United States pharmaceutical expenditures. So basically most pharmaceutical revenue comes from branded products. And, if you look at any annual report, it is pretty obvious that most of the profits come from their blockbusters still on patent. Also, notice all the price increases on those blockbusters which basically translates to pure profits for the pharma company in question. That can’t easily be done with generics. https://www.csrxp.org/big-pharma-earnings-watch-abbvie-amgen-and-gsk/
  14. I think you could have left out Butler/Dubose/Livingston - the only thing those guys can break out is a swell line dance.
  15. I'm just not sold on our 3rd wide receiver next year and that is without any injuries and Golden returning. Does the staff feel like one of the freshmen wide receivers can be an immediate impact guy? I guess it is hard to know, though, whether you have a Jeremiah Smith/Ryan Wingo or a Demond Demas/Evan Stewart. TE for fans seems to be a question mark as well. It's hard to know whether the staff feels like it has a solid 12 personnel package and whether it feels like it can replace Helms production. Any behind the scenes type info on the 2024 class on guys like Zina?
  16. @texifornia Did they ever tell us the severity of Derek Williams' knee injury and what they repaired at time of surgery?
  17. I thought Cole was - I did a quick google search and I didn't see it. Thanks for the clarification.
  18. safety will be fine. Corner is more of a question mark. Kobe Black, Wardell Mack, Santana Wilson, Jay'Vion Cole - most of those guys I haven't heard much about.
  19. Oh, kind of like Joe Burrow and Quinn Ewers.
  20. Fuck that. Let me know when Swift and Kelce go.
  21. Would you really hold that against her?
  22. Generics don’t make the largest companies profitable. In fact, I don’t know where things stand now, but 20 years ago, most pharmaceutical companies divested their OTC products and generics were an insignificant portion of sales. Basically all of their profits come from patented products and pharmaceutical companies attempt numerous workarounds to try to extend their patents as long as possible. Some of that has changed more recently due to the difficulty for companies to get generic biologics approved by the FDA, but still pharmaceutical companies don’t care about their generic products. All pharmaceutical profits are derived from innovation whether new targets or simply improved side effect profiles, method of delivery, etc. Anyway, it stands to reason that pharmaceutical companies strive to keep their product pipelines full. So, what do you think would happen if the industry were less profitable, had PEs similar to commodities, and earned exactly what the government thought was their right to earn? First, we would see good things - smaller sales forces, lower drug prices, less advertising. But later we would also see more mergers and acquisitions as the industry continued to mature. And we would see a decrease in development as the return on investment would justify fewer innovative, riskier products. Does this mean that innovation would die? Of course not. It would only slow down initially. However, in this scenario where government controls pharmaceutical prices, what happens as the government still has shortfalls in what it has budgeted to pay for pharmaceuticals? Well of course it would lower pharmaceutical prices even more. At some point without profits, development of pharmaceuticals comes to a crawl verses the rapid innovations that have occurred since penicillin was commercialized during WW2.
  23. My guess is that he led with NIL demands.
  24. Oregon and tOSU will be a battle. They should have the exact same chance to win it all. PSU will advance. We will advance. Georgia and Notre Dame will be a battle. Then it will be PSU vs the winner of the GA vs ND. And us vs the winner of OR vs OSU. PSU will lose because they aren't that good. And our game will be a tossup.
×
×
  • Create New...